TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Targovax ASA ( (GB:0RIS) ) is now available.
Circio Holding ASA has announced a proposed rights issue to raise up to NOK 50 million, with strong support from existing shareholders, including presubscription commitments totaling NOK 24.2 million. This capital injection will provide the company with a twelve-month cash runway to achieve significant pre-clinical development milestones and advance its gene and cell therapy programs, enhancing its industry positioning and stakeholder value.
More about Targovax ASA
Circio Holding ASA is a biotechnology company based in Oslo, Norway, specializing in developing novel circular RNA expression technology for gene and cell therapy. The company focuses on advancing its circVec circular RNA expression platform and has recently engaged in a feasibility study with a major global pharmaceutical company.
YTD Price Performance: 77.75%
Average Trading Volume: 4,530,369
Current Market Cap: NOK181.3M
Find detailed analytics on 0RIS stock on TipRanks’ Stock Analysis page.